Posted on 11月 22, 202211/22/22
Ready or Not, Biosimilar Adalimumab Brings the Heat in 2023
Posted on 11月 13, 202211/13/22
Establishing the Patient Access Mission During Clinical Development
Posted on 11月 10, 202211/10/22
Maximize In-Licensing Growth
Posted on 10月 24, 202210/24/22
David and Goliath: How Can First-Time Launchers Avoid Failure and Beat Big Pharma Launches
Posted on 10月 17, 202210/17/22
Developing Best-in-class Copay Programs for Gross-to-Net
Posted on 8月 30, 20228/30/22
Successful Early-Stage Out-Licensing Requirements
Posted on 8月 23, 20228/23/22
Social Determinants of Health – What Pharma Can Do!
Posted on 8月 18, 20228/18/22
Flipping the Script to Disrupt, Redefine and Accelerate the Patient Care Journey
Posted on 8月 5, 20228/5/22
Three Keys to Value for Unlocking the Promise of Cell Therapies
Posted on 8月 4, 20228/4/22